Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3032947 | 0.85 | ALDH1A1 (0.45) | ALDH1A1KDM4ESMN1; SMN2LMNAMAPT | |
| SCHEMBL8546197 | 0.85 | ALDH1A1 (0.45) | ALDH1A1KDM4ESMN1; SMN2LMNAMAPT | |
| SCHEMBL21510512 | 0.84 | KMT2A (0.48) | ALDH1A1KDM4ESMN1; SMN2LMNAMAPT | |
| SCHEMBL28516376 | 0.83 | ALDH1A1 (0.50) | ALDH1A1KDM4ESMN1; SMN2LMNAMAPT | |
| SCHEMBL498377 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4ESMN1; SMN2LMNAMAPT | |
| SCHEMBL3045965 | 0.82 | ALDH1A1 (0.42) | ALDH1A1KDM4ESMN1; SMN2LMNAMAPT | |
| SCHEMBL3036856 | 0.82 | SMN1; SMN2 (0.47) | ALDH1A1KDM4ESMN1; SMN2LMNAMAPT | |
| SCHEMBL1982503 | 0.81 | ALDH1A1 (0.53) | ALDH1A1KDM4ESMN1; SMN2LMNAMAPT | |
| SCHEMBL2998505 | 0.80 | CHRNB2 (0.46) | ALDH1A1KDM4ESMN1; SMN2LMNAMAPT | |
| SCHEMBL5357292 | 0.80 | ALDH1A1 (0.52) | ALDH1A1KDM4ESMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2721020-B1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS NC INC (US) | 2019-01-23 | — | — | EP | claimed |
| CN-103842355-A | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS INC | 2014-06-04 | — | — | CN | claimed |
| CN-103764646-A | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS INC | 2014-04-30 | — | — | CN | claimed |
| JP-2204471-A | — | — | None | — | — | JP | disclosed |
| US-20260083864-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | BAYER AG (DE) | 2026-03-26 | — | — | US | disclosed |
| EP-4611747-A1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | Genep Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4583926-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | Bayer Aktiengesellschaft (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4308551-B1 | NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER AG (DE) | 2025-04-09 | — | — | EP | disclosed |
| EP-3733186-B1 | NOVEL DIHYDROQUINAZOLINONE COMPOUND OR PHARMACOLOGICALLY ACCEPTABLE SALT, AND CELL GROWTH INHIBITOR | JAPANESE FOUND FOR CANCER RES (JP) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024097171-A1 | IMIDAZOLE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL INHIBITORS | GENEP INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024052550-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | BAYER AKTIENGESELLSCHAFT (DE) | 2024-03-14 | — | — | WO | disclosed |
| EP-1880720-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
| WO-2005042521-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
| EP-0387315-B1 | FLUORINATED ALKOXYL COMPOUNDS | MERCK PATENT GMBH (DE) | 1993-12-08 | — | — | EP | disclosed |
| JP-H02204471-A | PRODUCTION OF ARYLMETHYL (TRIFLUOROETHOXYPHENYL)KETONE | RHONE POULENC CHIM | 1990-08-14 | — | — | JP | disclosed |
| US-4925863-A | 1,3-DI(1,2,4-TRIAZOL-1-YL)-2-PROPANOL DERIVATIVES SUBSTITUTED WITH A STYRYL GROUP | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-05-15 | — | — | US | disclosed |
| US-4888340-A | Insecticides pyrazolines, compositions and use | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-12-19 | — | — | US | disclosed |
| US-4754067-A | REACTING A SYMETRICAL DIAMINOGUANIDINE WITH HYDROXYLAMINE HYDROCHLORIDE | AMERICAN CYANAMID COMPANY (US) | 1988-06-28 | — | — | US | disclosed |
| US-4649148-A | Insecticidal uses of diaminoguanidine hydrazone compounds | AMERICAN CYANAMID COMPANY (US) | 1987-03-10 | — | — | US | disclosed |
| US-4575560-A | ANTIFEEDING AGENTS | AMERICAN CYANAMID COMPANY (US) | 1986-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083864-A1 | CONTRAST AGENTS FOR USE IN DIAGNOSTIC COMPUTED TOMOGRAPHY IMAGING | CA13, CCR1, GALC | ALDH1A1 1811/4885KDM4E 4512/4885SMN1; SMN2 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.